Back to search

University of British Columbia

Investigating biomarkers of response to CDK4/6 inhibition in combination with anti-estrogen therapy in breast cancer cell lines

Abstract

dc:description

Breast cancer is the most common cancer diagnosed in women and remains the second leading cause of cancer related deaths. For decades, anti-estrogen therapy (AET) has been used to treat estrogen receptor positive (ER+) breast cancer. The development of novel targeted therapies, like cyclin dependent kinase 4/6 inhibitors (CDK4/6i), provide additional treatment options for women with late-stage disease. CDK4/6i in combination with AET has delayed cancer progression and is approved for use in metastatic ER+, human epidermal growth factor receptor 2 negative breast cancer. However, it is estimated that almost half of these patients don’t derive a meaningful benefit from this treatment combination, resulting in unnecessary drug toxicities. Furthermore, unnecessary cancer treatment is a burden to the healthcare system, particularly with expensive drugs like CDK4/6i which cost ~$8000 per month of treatment. The identification of predictive biomarkers represents a top cancer research priority. Biomarker testing improves treatment selection so that patients and our health care system derive maximal benefit from these effective but expensive drugs. To date, ER positivity remains the only molecular biomarker for CDK4/6i treatment selection. For this research, I performed a comprehensive literature review of CDK4/6i biomarkers and analyzed publicly available molecular/clinical databases to identify potential biomarkers. I then conducted in vitro tests of palbociclib (CDK4/6i) and tamoxifen (AET) on a comprehensive panel of breast cancer cell lines. From this, I optimized the in vitro experimental assays to ensure they measured the cytostatic activity of palbociclib to accurately rank drug efficacy amongst the cell lines. Next, using reverse phase protein array (RPPA), I performed a discovery-based proteomic analysis to identify biomarkers of resistance to palbociclib +/- tamoxifen. My analysis of public databases failed to identify any statistically significant biomarkers, further highlighting the need for biomarker research. Western blot analysis identified p16 overexpression and Rb loss as markers of resistance to palbociclib. RPPA analyses identified an additional thirteen differentially expressed proteins associated with palbociclib resistance. I also identified twelve proteomic biomarkers of resistance to the combination therapy. This research identifies predictive biomarker candidates for validation and highlights the importance of experimental assay optimization for translatable in vitro testing.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Reproductive and Developmental Sciences
Grantor dc:publisher
University of British Columbia
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Bittner, Madison
Contributors dc:contributor
  • Carey, M. S.

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/83611

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Bittner, Madison. Investigating biomarkers of response to CDK4/6 inhibition in combination with anti-estrogen therapy in breast cancer cell lines. master's thesis, University of British Columbia, 2022. http://hdl.handle.net/2429/83611